Clario aquires imaging provider NeuroRx

The “strategic” acquisition is set to further support the comapny’s scientific expertise while boosting drug development.

US based medical technology company Clario has announced its acquisition of NeuroRx, a leader in imaging analysis with expertise in multiple sclerosis.

NeuroRx has built a reputation for providing clinical trials with imaging-related services from protocol assistance to the interpretation and reporting of data, having further supported the approvals of numerous neurological therapies, including 12 FDA-approved multiple-sclerosis drugs since 2011.

“We’re excited to welcome NeuroRx to Clario,” said Clario’s CEO, Chris Fikry, “This strategic acquisition reinforces our strong leadership in imaging and further expands our capabilities in neuroscience an area of immense importance in advancing medical innovation. By augmenting our expertise in this critical therapeutic area, we are even better positioned to support our customers in developing life-changing drugs.”

In addition to the NeuroRx acquisition, Clario last week announced a signed definitive agreement to acquire WCG’s eCOA business. Together, the two acquisitions are expected to strengthen Clario’s scientific expertise and service delivery capabilities in the neuroscience therapeutic area.

NeuroRx’s founder and CEO, Douglas Arnold, will be joining Clario as Senior Scientific Advisor. “Since 2002, our team at NeuroRx has been dedicated to advancing imaging science to support the development of breakthrough treatments for neurological diseases,” he said. “With experience in over 300 clinical trials, we have seen firsthand the impact that advanced image analysis can have on drug development. Joining Clario allows us to expand our reach, increase innovation, and broaden our impact on drug development.”

Joyce Suhy, Ph. D, VP of Clario’s Medical Imaging and Specialty Solutions added: “Neuroscience is one of the most challenging frontiers in medicine, and tackling it requires deep expertise and unwavering commitment”.

“With NeuroRx joining our organization, we are gaining a team of scientists and imaging capabilities that have played a pivotal role in advancing multiple sclerosis drug development, as well supported treatments for Huntington’s, Parkinson’s, and Alzheimer’s diseases. I couldn’t be more excited about what that means for Clario, our customers, and their patients.”